Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Patent News

The Patent Application Discloses Compositions for Reducing Skin Fat

Author(s): Marta Woźniak-Budych* and Bartosz Tylkowski

Volume 29, Issue 41, 2023

Published on: 18 December, 2023

Page: [3340 - 3342] Pages: 3

DOI: 10.2174/0113816128280165231212070355

Price: $65

« Previous
[1]
Femminò S, Pagliaro P, Penna C. Obesity and cardioprotection. Curr Med Chem 2020; 27(2): 230-9.
[http://dx.doi.org/10.2174/0929867326666190325094453] [PMID: 30907304]
[2]
Lenharo M. Anti-obesity drug also protects against heart disease - What happens next? Nature 2023; 620(7974): 480.
[http://dx.doi.org/10.1038/d41586-023-02528-2] [PMID: 37568000]
[3]
Sidik S. Beyond ozempic: Brand-new obesity drugs will be cheaper and more effective. Nature 2023; 619(7968): 19.
[http://dx.doi.org/10.1038/d41586-023-02092-9] [PMID: 37369789]
[4]
Recalde M, Pistillo A, Davila-Batista V, et al. Longitudinal body mass index and cancer risk: A cohort study of 2.6 million Catalan adults. Nat Commun 2023; 14: 1-11.
[http://dx.doi.org/10.1038/s41467-023-39282-y]
[5]
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers 2023; 15(2): 485.
[http://dx.doi.org/10.3390/cancers15020485] [PMID: 36672434]
[6]
Wu X, Xu M, Geng M, et al. Targeting protein modifications in metabolic diseases: Molecular mechanisms and targeted therapies. Signal Transduct Target Ther 2023; 8(1): 220.
[http://dx.doi.org/10.1038/s41392-023-01439-y]
[7]
Jin X, Qiu T, Li L, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B 2023; 13(6): 2403-24.
[http://dx.doi.org/10.1016/j.apsb.2023.01.012] [PMID: 37425065]
[8]
Ahmad B, Serpell CJ, Fong IL, Wong EH. Molecular mechanisms of adipogenesis: The anti-adipogenic role of amp-activated protein kinase. Front Mol Biosci 2020; 7: 76.
[http://dx.doi.org/10.3389/fmolb.2020.00076] [PMID: 32457917]
[9]
Li X, Liu Q, Pan Y, Chen S, Zhao Y, Hu Y. New insights into the role of dietary triglyceride absorption in obesity and metabolic diseases. Front Pharmacol 2023; 14: 1097835.
[http://dx.doi.org/10.3389/fphar.2023.1097835] [PMID: 36817150]
[10]
Anti-obesity Drugs Market Size & Share | Global Report.. Available from: https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783 (Accessed August 31, 2023)
[11]
] Compositions and methods for reducing skin fat.. Available from: https://patents.justia.com/patent/20230270701 (Accessed November 3, 2023)
[12]
Zhu Y, Kim SQ, Zhang Y, Liu Q, Kim KH. Pharmacological inhibition of acyl-coenzyme A: Cholesterol acyltransferase alleviates obesity and insulin resistance in diet-induced obese mice by regulating food intake. Metabolism 2021; 123: 154861.
[http://dx.doi.org/10.1016/j.metabol.2021.154861] [PMID: 34371065]
[13]
Guan C, Niu Y, Chen SC, et al. Structural insights into the inhibition mechanism of human sterol O-acyltransferase 1 by a competitive inhibitor. Nat Commun 2020; 11: 1-11.
[http://dx.doi.org/10.1038/s41467-020-16288-4]
[14]
Schmidt NM, Wing PAC, Diniz MO, et al. Targeting human Acyl-CoA: Cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. Nat Commun 2021; 12: 1-14.
[http://dx.doi.org/10.1038/s41467-021-22967-7]
[15]
Ferrara PJ, Rong X, Maschek JA, et al. Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle. J Clin Invest 2021; 131(8): e135963.
[http://dx.doi.org/10.1172/JCI135963] [PMID: 33591957]
[16]
Compositions and methods for regulating body weight and metabolic syndromes.. Available from: https://patents.justia.com/patent/20190365679(Accessed September 27, 2023)

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy